← Scoopfeeds — Intelligent news, curated.
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results
business

Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results

Yahoo Finance · Jun 26, 2026, 11:11 AM · Also reported by 3 other sources

Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Cantor Fitzgerald reiterates CrowdStrike stock rating on strong results Investing.com Cantor Fitzgerald reiterates ON Semiconductor stock rating on acquisition Investing.com Cantor Fitzgerald reiterates JFrog stock rating on cloud growth

More in business

Investing.com
Deutsche Bank cuts Synaptics stock rating on ON acquisition deal
Investing.com
Have lithium prices peaked? Bernstein says the rally may still have room to run
Bloomberg Markets
US Pet Market Set to Surpass $250 Billion
Yahoo Finance
Stock Market Week Ahead: Rotating, For Now, Away From The AI Boom
Investing.com
Venezuela welcomes 1,600 foreign rescuers in urgent search for quake survivors
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop